ScienceDex / Researcher record
Aaron Cravens
- Revel Pharmaceuticals Inc. (no department on record)
From the FY2025 NIH awards this investigator leads as contact PI. The department is the award's.
- Early Career
NIH Funding · FY2025
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2025 | $1,722,227 | 2 | #8,351 |
| 2026 | $923,550 | 1 | #20,622 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY2025 · selected2 records
- FY20261 record
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 16425023Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2025 through FY2026Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2027.
FY2025 award records by amount
NIH award records listing Aaron Cravens as a PI. Multi-PI records show the full award amount for context.
- 2R44AG084351-02R44Contact PIDevelopment of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts$1.4Maward amount
- 1R43EY036695-01A1R43Contact PIDevelopment of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy$358.1Kaward amount
Award organization
Organizations that administered FY2025 awards listing Aaron Cravens as a PI.
FY2025 award administered by Revel Pharmaceuticals Inc. (CA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2025First NIH AwardRevel Pharmaceuticals Inc.
- 2025$500K Cumulative Funding
- 2025$1M Cumulative Funding
- 2025Entered Top 50% NationallyRanked #8351
- 2026$2M Cumulative Funding